Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus nab-paclitaxel and carboplatin in advanced head and neck squamous cell carcinoma
ChiCTR2300070675Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa, paclitaxel and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
retlirafusp alfapaclitaxelcarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300070675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070675.